• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Commentary: Biosimilars in the treatment of retinopathy of prematurity.

作者信息

Soni Tanvi, Kohli Piyush

机构信息

Department of Cornea, Advanced Eye Center, Post-Graduate Medical Institute and Medical Research Institute, Chandigarh, India.

Department of Vitreo-Retinal Services, C.L. Gupta Eye Hospital, Moradabad, Uttar Pradesh, India.

出版信息

Indian J Ophthalmol. 2023 Feb;71(2):416-417. doi: 10.4103/ijo.IJO_2254_22.

DOI:10.4103/ijo.IJO_2254_22
PMID:36727330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10228922/
Abstract
摘要

相似文献

1
Commentary: Biosimilars in the treatment of retinopathy of prematurity.评论：生物类似药在早产儿视网膜病变治疗中的应用
Indian J Ophthalmol. 2023 Feb;71(2):416-417. doi: 10.4103/ijo.IJO_2254_22.
2
Commentary: Retinopathy of prematurity: Where do we stand?评论：早产儿视网膜病变：我们目前的状况如何？
Indian J Ophthalmol. 2021 Aug;69(8):2132-2133. doi: 10.4103/ijo.IJO_1288_21.
3
Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.生物类似雷珠单抗单药治疗早产儿视网膜病变的疗效。
Indian J Ophthalmol. 2023 Feb;71(2):411-415. doi: 10.4103/ijo.IJO_973_22.
4
Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.大孕周早产儿玻璃体内注射抗血管内皮生长因子治疗侵袭性早产儿视网膜病变的荧光素血管造影
Acta Ophthalmol. 2014 Dec;92(8):810-3. doi: 10.1111/aos.12461. Epub 2014 Jun 9.
5
Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.早产儿后部进展性视网膜病变治疗效果良好。
Eur J Ophthalmol. 2021 Jan;31(1):179-183. doi: 10.1177/1120672119886989. Epub 2019 Nov 13.
6
Retinopathy of prematurity screening with mobile phones.使用手机进行早产儿视网膜病变筛查。
Eur J Ophthalmol. 2016 Apr 12;26(3):e58. doi: 10.5301/ejo.5000749.
7
Technique for Infant Intravitreal Injection in Treatment of Retinopathy of Prematurity.用于治疗早产儿视网膜病变的婴儿玻璃体内注射技术。
Retina. 2017 Nov;37(11):2188-2190. doi: 10.1097/IAE.0000000000001561.
8
Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity.婴儿期伴有侵袭性早产儿后部视网膜病变的缓慢进行性周边血管形成。
J AAPOS. 2020 Oct;24(5):323-326. doi: 10.1016/j.jaapos.2020.07.007. Epub 2020 Oct 9.
9
Do we screen very premature babies too early for retinopathy of prematurity?我们对极早产儿筛查早产儿视网膜病变是否为时过早？
Eye (Lond). 2016 Apr;30(4):636-7. doi: 10.1038/eye.2015.279. Epub 2016 Jan 22.
10
Dexamethasone Eye Drops for the Treatment of Retinopathy of Prematurity.地塞米松滴眼液用于治疗早产儿视网膜病变
Ophthalmol Retina. 2022 Feb;6(2):181-182. doi: 10.1016/j.oret.2021.09.002. Epub 2021 Sep 10.

本文引用的文献

1
Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.生物类似雷珠单抗单药治疗早产儿视网膜病变的疗效。
Indian J Ophthalmol. 2023 Feb;71(2):411-415. doi: 10.4103/ijo.IJO_973_22.
2
Future of anti-VEGF: biosimilars and biobetters.抗血管内皮生长因子药物的未来：生物仿制药和生物改良药。
Int J Retina Vitreous. 2022 Jan 4;8(1):2. doi: 10.1186/s40942-021-00343-3.
3
Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy.早产儿视网膜病变经玻璃体腔内抗血管内皮生长因子治疗后再激活的描述和处理。
Curr Opin Ophthalmol. 2021 Sep 1;32(5):468-474. doi: 10.1097/ICU.0000000000000786.
4
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society.抗血管内皮生长因子在早产儿视网膜病变管理中的应用：印度早产儿视网膜病变学会成员的调查。
Indian J Ophthalmol. 2021 Aug;69(8):2158-2163. doi: 10.4103/ijo.IJO_200_21.
5
International Classification of Retinopathy of Prematurity, Third Edition.国际早产儿视网膜病变分类，第三版。
Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016/j.ophtha.2021.05.031. Epub 2021 Jul 8.
6
Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial.比较康柏西普与雷珠单抗治疗早产儿视网膜病变的临床疗效：一项多中心前瞻性随机对照临床试验。
Br J Ophthalmol. 2022 Jul;106(7):975-979. doi: 10.1136/bjophthalmol-2020-318026. Epub 2021 Feb 26.
7
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.评论：印度视网膜疾病生物类似药的使用：挑战与担忧
Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.
8
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
9
A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.一项基于大病例系列的抗 VEGF 治疗后早产儿视网膜病变复发或治疗失败的诊断和治疗算法的建议。
Graefes Arch Clin Exp Ophthalmol. 2020 Apr;258(4):767-772. doi: 10.1007/s00417-020-04605-y. Epub 2020 Jan 17.
10
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.雷珠单抗与激光治疗用于治疗极低出生体重早产儿视网膜病变（RAINBOW）：一项开放标签随机对照试验。
Lancet. 2019 Oct 26;394(10208):1551-1559. doi: 10.1016/S0140-6736(19)31344-3. Epub 2019 Sep 12.